<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: It Takes The FDA How Long To Approve Generics?</title>
	<atom:link href="http://www.pharmalot.com/2008/06/it-takes-the-fda-how-long-to-approve-generics/feed" rel="self" type="application/rss+xml" />
	<link>http://www.pharmalot.com/2008/06/it-takes-the-fda-how-long-to-approve-generics/</link>
	<description>News, Comment and Conversation</description>
	<pubDate>Fri, 10 Feb 2012 22:41:40 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.2</generator>
		<item>
		<title>By: Dan</title>
		<link>http://www.pharmalot.com/2008/06/it-takes-the-fda-how-long-to-approve-generics/#comment-360117</link>
		<dc:creator>Dan</dc:creator>
		<pubDate>Sat, 14 Jun 2008 02:24:36 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/?p=14115#comment-360117</guid>
		<description>My opnion, but there seems to be a correlation between the PDUFA and priority reviews doubling in only a period of a few years. Eight years ago, if a pharma company paid the FDA a solid million dollars aside from the PDUFA, they have bought a priority review. A little known fact.</description>
		<content:encoded><![CDATA[<p>My opnion, but there seems to be a correlation between the PDUFA and priority reviews doubling in only a period of a few years. Eight years ago, if a pharma company paid the FDA a solid million dollars aside from the PDUFA, they have bought a priority review. A little known fact.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: CMC guy</title>
		<link>http://www.pharmalot.com/2008/06/it-takes-the-fda-how-long-to-approve-generics/#comment-360094</link>
		<dc:creator>CMC guy</dc:creator>
		<pubDate>Sat, 14 Jun 2008 00:14:04 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/?p=14115#comment-360094</guid>
		<description>While poor performance indeed a limited resources verses burden seems to be largely responsible as "ANDA submissions have increased at more than double the rate of review resources in the last 5 years".  There were 989 submissions in 2006 so is a huge amount of information to deal with.  I don't know how many Chemistry Reviewers FDA has in total much less ones dedicated to OGD (to those who do not know Chemistry includes Chemistry, Manufacturing and Controls, CMC, and is typically bulk of an ANDA unlike NDAs which are largely Clinical.  CMC Sections are highly technical and diverse in content).  Looking at time factor alone may be a bad metric as impression is iterative since appears other areas don't really engage until Chemistry passes.

The fact that only 4% get approve/approvable (96% reject) is very curious.  Although some generics submissions come from inexperienced manufacturers there are many that should know how to it right.</description>
		<content:encoded><![CDATA[<p>While poor performance indeed a limited resources verses burden seems to be largely responsible as &#8220;ANDA submissions have increased at more than double the rate of review resources in the last 5 years&#8221;.  There were 989 submissions in 2006 so is a huge amount of information to deal with.  I don&#8217;t know how many Chemistry Reviewers FDA has in total much less ones dedicated to OGD (to those who do not know Chemistry includes Chemistry, Manufacturing and Controls, CMC, and is typically bulk of an ANDA unlike NDAs which are largely Clinical.  CMC Sections are highly technical and diverse in content).  Looking at time factor alone may be a bad metric as impression is iterative since appears other areas don&#8217;t really engage until Chemistry passes.</p>
<p>The fact that only 4% get approve/approvable (96% reject) is very curious.  Although some generics submissions come from inexperienced manufacturers there are many that should know how to it right.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Atlex</title>
		<link>http://www.pharmalot.com/2008/06/it-takes-the-fda-how-long-to-approve-generics/#comment-360084</link>
		<dc:creator>Atlex</dc:creator>
		<pubDate>Fri, 13 Jun 2008 23:35:25 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/?p=14115#comment-360084</guid>
		<description>Nathan,

I think that the vast majority of these delays apply to generics that are the 5th, 6th, 10th, 12th to market, not the first 2 or 3.

Atlex</description>
		<content:encoded><![CDATA[<p>Nathan,</p>
<p>I think that the vast majority of these delays apply to generics that are the 5th, 6th, 10th, 12th to market, not the first 2 or 3.</p>
<p>Atlex</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Dan</title>
		<link>http://www.pharmalot.com/2008/06/it-takes-the-fda-how-long-to-approve-generics/#comment-360077</link>
		<dc:creator>Dan</dc:creator>
		<pubDate>Fri, 13 Jun 2008 22:44:38 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/?p=14115#comment-360077</guid>
		<description>It's somewhat Pavlovian.  Let's virtually eliminate the requirements of approval mandated to the branded companies, so we can increase the volume of generics.  Then the closure time seems to be longer than the development process.

Remember the FDA's mission statement:

"To promote and protect public health"

Enron had a mission statement, too.</description>
		<content:encoded><![CDATA[<p>It&#8217;s somewhat Pavlovian.  Let&#8217;s virtually eliminate the requirements of approval mandated to the branded companies, so we can increase the volume of generics.  Then the closure time seems to be longer than the development process.</p>
<p>Remember the FDA&#8217;s mission statement:</p>
<p>&#8220;To promote and protect public health&#8221;</p>
<p>Enron had a mission statement, too.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Nathan</title>
		<link>http://www.pharmalot.com/2008/06/it-takes-the-fda-how-long-to-approve-generics/#comment-360069</link>
		<dc:creator>Nathan</dc:creator>
		<pubDate>Fri, 13 Jun 2008 22:00:18 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/?p=14115#comment-360069</guid>
		<description>Big deal -- the FDA is taking forever to review NDA's too.  It wouldn't be exactly fair if they were late reviewing NDA's but then were on-time reviewing ANDA's.  They need to be consistant with both in order to give a "fair" lifetime for brand-name drugs.</description>
		<content:encoded><![CDATA[<p>Big deal &#8212; the FDA is taking forever to review NDA&#8217;s too.  It wouldn&#8217;t be exactly fair if they were late reviewing NDA&#8217;s but then were on-time reviewing ANDA&#8217;s.  They need to be consistant with both in order to give a &#8220;fair&#8221; lifetime for brand-name drugs.</p>
]]></content:encoded>
	</item>
</channel>
</rss>

<!-- Dynamic Page Served (once) in 0.152 seconds -->

